10-Q: The Greater Cannabis Company Reports Third Quarter 2024 Results Amidst Ongoing Financial Challenges

The Greater Cannabis Company reported no revenue and a net loss for the third quarter of 2024, while continuing to focus on the development of cannabinoid therapeutics.

Summary

• The Greater Cannabis Company reported no revenue for the three and nine months ended September 30, 2024 and 2023.
• The company's operating expenses for the nine months ended September 30, 2024 were $118,651, a decrease from $131,337 in the same period of 2023.
• The net loss for the nine months ended September 30, 2024 was $135,693, compared to a net loss of $141,541 for the same period in 2023.
• The company had $62,282 in cash as of September 30, 2024, a decrease from $166,859 at the end of 2023.
• The company has outstanding notes payable to third parties totaling $171,437 as of September 30, 2024.
• The company is focused on developing and commercializing cannabinoid therapeutics, particularly for neuropsychiatric disorders, and is conducting clinical studies which are expected to require an investment of up to $1,000,000 and up to two years to finalize.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with no revenue, significant losses, and a going concern warning. While there is a focus on future development, the current financial state is weak.

Positives

• Operating expenses have decreased year-over-year, indicating some cost control.
• The company is actively pursuing the development of a novel cannabinoid therapeutic, which could provide future revenue streams.
• The company has a license agreement with Shaare Zedek Scientific Ltd. for a cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinsons disease, Alzheimers disease and other neuropsychiatric disorders.

Negatives

• The company has generated no revenue for the reported periods.
• The company continues to incur net losses.
• Cash reserves have significantly decreased.
• The company has a negative working capital of $798,592.
• There is substantial doubt about the company's ability to continue as a going concern through September 2025.

Risks

• The company may not be able to remediate identified material weaknesses in internal control over financial reporting.
• The company may fail to meet the requirements of agreements under which it acquired business interests.
• The company may be unable to secure additional financing to sustain its development and growth plans.
• The company may not be able to attract, retain, and motivate qualified personnel.
• The company faces risks related to the inherent uncertainty of business operations, including profitability and cost estimates.
• The company faces risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for planned development projects.
• The company faces risks related to environmental regulation and liability and tax assessments.

Future Outlook

The company plans to conduct clinical studies on its cannabinoid-based therapeutic and concentrate on cannabis-related investment and development opportunities. The clinical studies are expected to require an investment of up to $1,000,000 and up to two years to finalize.

Management Comments

• Management believes that the company's current focus on cannabinoid therapeutics offers greater potential for growth and ultimate profitability.
• Management expects to continue to incur negative cash flows until the business generates sufficient cash inflows to finance operations and debt service requirements.

Industry Context

The company is operating in the competitive and evolving cannabis and biotechnology sectors, focusing on the development of cannabinoid-based therapeutics. The company's focus on neuropsychiatric disorders aligns with a growing interest in alternative treatments for these conditions.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry norms for companies that have been operating for several years.
• Many comparable companies in the biotechnology and pharmaceutical sectors are actively generating revenue from product sales or licensing agreements.
• The company's cash burn rate and negative working capital are concerning when compared to industry benchmarks for early-stage companies.
• Companies like GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) and Canopy Growth have demonstrated the potential for revenue generation in the cannabinoid space, but also highlight the challenges of achieving profitability.
• The company's reliance on external funding and its going concern status are not uncommon for early-stage biotech companies, but the lack of revenue and significant losses are concerning.

Related Party Transactions

• The company has loans payable to related parties, including Elisha Kalfa and Yonah Kalfa, and Fernando Bisker and Sigalush, LLC, totaling $260,000.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern status.
• Employees may be impacted by potential layoffs or reduced compensation if the company is unable to secure additional funding.
• Customers are not currently impacted as the company has no product sales.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to conduct clinical studies on its cannabinoid-based therapeutic.
• The company will continue to seek cannabis-related investment and development opportunities.
• The company needs to secure additional funding to continue operations.

Key Dates

Keywords

cannabinoid therapeutics, clinical studies, financial results, net loss, operating expenses, going concern, biotechnology, pharmaceuticals, drug development, neuropsychiatric disorders